CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 234 enrolled
Drug / intervention
LUM Imaging Systemcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03321929
NCT03321929Phase 2Completed

Feasibility Study Phase C: Expansion Into Multiple Institutions for Training in the Use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer

Lumicell, Inc.·interventional·Posted Oct 26, 2017·Updated May 1, 2023

In Brief

A Phase 2 clinical trial evaluating LUM Imaging System for Breast Cancer. Completed, enrolled 234 participants across 16 sites.

Detailed Summary

This is a non-randomized, open-label, multi-site study to collect safety and efficacy data on an intraoperative imaging system, the LUM Imaging System (LUM015 imaging agent in conjunction with the LUM imaging device), in identifying residual cancer in the tumor bed of female breast cancer patients. During the study, study physicians and clinical staff will complete hands-on training in anticipation of the upcoming pivotal study. Site-specific or user-specific issues related to the use of the device will be identified and addressed. Additionally, the data collected in the study will be used to continue training the tumor detection algorithm of the device. In this study, patients will be injected with LUM015 prior to surgery. The study physicians will perform lumpectomy procedures according to his or her institution's standard of care practice. After the main specimen removal is completed, the study physician will use the LUM Imaging Device to image the tumor bed. Therapeutic shaves will be removed based on the recommendation of the LUM Imaging System. Patients will be followed until their first standard of care post-operative follow-up visit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 26, 2017
Enrollment StartFeb 6, 2018
Primary CompletionApr 10, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.7 years ago

Interventions

LUM Imaging Systemcombination

Drug: LUM015 Device: LUM 2.6 Imaging Device